Author

R. O'Regan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

, I. Makhoul· 1 shared A. Bardia· 1 shared A. Bild· 1 shared A. L. Cohen· 1 shared A. O'Dea· 1 shared C. Ma· 1 shared C. Urech· 1 shared D. Wyczechowska· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

, I. Makhoul

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancer

M. Vigolo, C. Urech, S. Lamy, G. Monticone, J. Zabaleta, F. Hossain, D. Wyczechowska, L. Del Valle, R. O'Regan, L. Miele, R. Lehal, S. Majumder

This paper evaluates the efficacy and safety of CB-103, a Notch inhibitor, in preclinical breast cancer models, showing synergistic effects with existing therapies.

bioRxiv · Jul 6, 2023Cancer Biology

Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitors

J. I. Griffiths, J. Chen, P. A. Cosgrove, A. O'Dea, P. Sharma, C. Ma, M. Trivedi, K. Kalinsky, K. B. Wisinski, R. O'Regan, , I. Makhoul, L. M. Spring, A. Bardia, F. R. Adler, A. L. Cohen, , A. Bild

This study examines how breast cancer tumors evolve during early stage treatment with combination CDK and endocrine inhibitors, finding convergent resistance pathways and increased subclonal diversity with combination therapy.

bioRxiv · Jan 19, 2021 · PreprintCancer Biology